Participated · Series B · Jan 2026

Diagonal Therapeutics engineers first-in-class clustering antibodies that aim to repair faulty cell-signaling pathways driving severe genetic disorders. Its DIAGONAL Product Engine combines proprietary computational and experimental methods to overcome traditional antibody discovery challenges and produce optimized therapeutics. The lead program, DIAG723, targets the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension and is the primary focus of upcoming clinical advancement. Beyond this, the company is building a pipeline of selective clustering antibodies addressing diseases in hematology, hepatology, and nephrology. Funds from the latest raise will be deployed to progress DIAG723 and further pipeline development. Diagonal is led by founder and CEO Alex Lugovskoy and has attracted several blue-chip life-science investors, underscoring strong industry confidence in its platform.

Participated · Series C · Apr 2025

Attovia leverages its ATTOBODY platform, which uses spatial positioning technology to achieve biparatopic target engagement, to develop multi-specific biologics for immune-mediated diseases. Its lead candidate, ATTO-1310, is a half-life extended anti‑IL31 biologic currently in Phase 1 for chronic pruritus of unknown origin and other pruritic conditions. The company is advancing ATTO-3712, a half-life extended anti‑IL13 x IL31 bispecific, and plans to start Phase 1 studies for ATTO-3712 in the second half of 2025. Earlier-stage programs include ATTO-004, a multi-specific candidate targeting IBD, plus two discovery-stage multi-specific programs. Attovia was founded by CEO Tao Fu and is positioned to use new capital to advance its clinical and discovery-stage pipeline. The company announced board expansion alongside its financing. Attovia is developing a pipeline of biotherapeutics with an initial focus on immune-mediated diseases and uses the ATTOBODY™ biparatopic biologics platform. The platform is designed to generate binders that offer stronger efficacy and access a broader universe of druggable epitopes compared to traditional approaches. Its lead programs are ATTO-1310, a potential first-in-class, long half-life anti-IL31 ATTOBODY, and ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY targeting atopic dermatitis and other pruritic diseases. ATTO-1310 is in IND-enabling studies and is on track to enter the clinic around year-end 2024; Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025. The company raised $105M in Series B financing, bringing total funding to $165M, and plans to use proceeds to advance lead programs to initial clinical data readouts, expand its immunology and inflammation pipeline, and further develop the ATTOBODY platform. Led by CEO Tao Fu, Attovia is also developing discovery-stage programs to expand the ATTOBODY footprint to novel, difficult-to-drug targets and multi-specific combinations. Attovia Therapeutics is a California-based company developing a pipeline of biotherapeutics for immune-mediated disease and oncology built on the Attobody™ biparatopic nanobody platform. The platform produces small-format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Attovia’s lead program is an Attobody to treat immune disease; the company is progressing multiple programs and plans to initiate additional discovery projects. The company will use proceeds to achieve clinical proof-of-concept on its lead program, nominate additional development candidates across immunology and oncology, and continue to advance the Attobody technology. Attovia was launched by Alamar Biosciences and Frazier Life Sciences and will receive an exclusive worldwide license to the Attobody platform and associated IP and pipeline assets in exchange for equity and potential milestones and royalties. Tao Fu will serve as CEO; the leadership team includes CSO Petter Veiby, CTO Hangjun Zhan, and CBO Zaneta Odrowaz.

Participated · Series C · Jul 2024

Scorpion Therapeutics is a clinical-stage oncology company that builds selective small-molecule precision medicines using an integrated platform spanning cancer biology, medicinal chemistry, and data sciences. Its lead program is STX-478, an allosteric, mutant-selective PI3Kα inhibitor that entered a Phase 1/2 trial in 2023 and has progressed into multiple expansion cohorts across solid tumors and breast cancer as monotherapy and in combination. The company also advances a clinical-stage EGFR inhibitor franchise including STX-721 and STX-241, plus a discovery pipeline of next-generation precision oncology therapies. Scorpion plans to use the proceeds from the Series C to expand clinical development of STX-478 and continue advancing its clinical and discovery-stage programs. Management states the company is on-track to disclose initial safety, PK/PD, and preliminary efficacy data at a future academic conference. The financing strengthens Scorpion’s balance sheet to support rapid development of its pipeline. Scorpion Therapeutics has developed a drug-hunting engine that integrates translational medicine, chemical biology, medicinal chemistry, and data science to discover targeted cancer therapies. The company is building a pipeline in three tracks: best- or first-in-class candidates against known high-impact oncogenes; candidates against historically “undruggable” non-enzymatic targets; and a new wave of protein targets discovered by Scorpion. Proceeds from the financing will support continued development of the platform and advancement of multiple therapeutic candidates across varied biological approaches for tumor targeting. Scorpion plans to name its first development candidate in 2021 and initiate clinical trials in 2022. Since its founding in the first quarter of 2020, the company has raised approximately $270 million. Scorpion Therapeutics builds a drug discovery and development engine that integrates cancer genomics, medicinal chemistry, and translational medicine to create next-generation small-molecule oncology therapies. The company aims to deliver best- and first-in-class small molecules that are safe, well-tolerated, and provide deeper, more durable responses for patients with treatment-resistant or untreatable cancers. Scorpion’s initial strategy focuses on three efforts: designing best/first-in-class drugs against known oncogenes; drugging classically undruggable cancer targets; and discovering and rapidly drugging novel transformative targets. It was founded by a team of drug developers and cancer researchers including Gary D. Glick, Keith Flaherty, Gaddy Getz, and Liron Bar-Peled, and is led by an experienced scientific team including Darrin Stuart, Angel Guzman Perez, and Erica Jackson. The company closed a $108 million Series A financing to advance its “Precision Oncology 2.0” platform and preclinical pipeline. The financing will support its discovery engine, next-generation chemistry, and translational efforts to move programs toward clinical development.

Participated · Equity · May 2024

Bicycle Therapeutics draws on Sir Gregory Winter’s Nobel-winning research to develop ‘bicycle’ molecules: fully synthetic short peptides constrained with small-molecule scaffolds that form two loops to stabilize their geometry and penetrate solid tumours. The company is developing these precision-guided therapeutics across multiple high-value cancer programs and an earlier discovery pipeline, and has partnered with other research and therapeutics organizations to broaden application to different tumours. Bicycle is headquartered in Cambridge, UK, with many key functions and leadership team members located in Cambridge, Mass. The company completed a $555M equity financing via a private placement that includes participation from new and existing investors. That financing strengthens its balance sheet to a pro forma cash position of approximately $1B and extends its expected financial runway into the second half of 2027. Management says the proceeds will support progress across multiple programs and discovery-stage work, with multiple catalysts expected in the second half of 2024. Bicycle Therapeutics is a Cambridge, UK–based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform. The company develops chemically synthesized medicines intended to address therapeutic needs unreachable with existing treatment modalities. Its internal focus is oncology, where Bicycle is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators, and T‑cell modulators for cancers of high unmet medical need. Led by CEO Kevin Lee, Ph.D., the company is also applying its platform to other areas. Bicycle was awarded a grant from Innovate UK to develop the next generation of novel antibiotics. The grant will support development of its antibiotic programs alongside its ongoing oncology pipeline. Bicycle Therapeutics builds drugs from its proprietary bicyclic peptide (Bicycle®) platform, which combines antibody-like affinity, small-molecule distribution kinetics for rapid tumor penetration, and tuneable peptide pharmacokinetics with renal clearance. Its lead program, BT1718, is a first-in-class Bicycle Drug Conjugate® targeting MT1‑MMP and is intended to deliver toxic payloads selectively to tumors. BT1718 was expected to enter the clinic in 2017 in partnership with Cancer Research UK. The company intends to use the Series B proceeds to advance multiple drug candidates and fund additional pipeline programs through early clinical development, with the first additional program to be selected in the second half of 2017. Bicycle highlights collaborations and a pipeline that includes toxin drug conjugates and immune modulators for oncology and other diseases. The company is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. The Series B financing provides new capital to move BT1718 rapidly toward the clinic and advance preclinical programs. Bicycle Therapeutics is a Cambridge, UK-based biotech focused on developing bicyclic peptides. The company has a proprietary bicyclic peptide–based technology that enables discovery of a new class of drug candidates with antibody-like affinity and selectivity in smaller, chemically synthesized molecules. It applies the platform across oncology, respiratory, inflammatory and ophthalmology programs as agonists, antagonists or for delivering payloads. Management is led by CEO Rolf Günther and Chairman Andrew Sandham. The company raised $32M to fund clinical development of therapeutic bicycle drug candidates in oncology. Bicycle intends to leverage pharma partnerships to advance its oncology programs; its first partnership with ThromboGenics targets an ophthalmology indication including diabetic macular edema. Bicycle Therapeutics develops a proprietary bicyclic peptide technology platform that generates peptide therapeutics with antibody-like selectivity and specificity and manufacturing economics similar to new chemical entities. The company is applying the platform to drug discovery in oncology, metabolic and inflammatory diseases and plans to make the platform accessible for collaborative discovery with pharma partners. Bicycle has transitioned from technology development to active drug discovery, expanding efforts across multiple drug target classes using its bicyclic peptide libraries, high-throughput screening and lead optimisation capabilities. The company is based at the Babraham Research Campus in Cambridge and was co-founded by Sir Gregory Winter and Professor Christian Heinis; its leadership includes CEO Rolf Günther and CSO Dr. John Tite. Financially, Bicycle secured a tranched equity financing to support selection and progression of drug candidates.

Participated · Series C · May 2024

Ajax Therapeutics is developing next‑generation, selective JAK inhibitors to address unmet needs in myeloproliferative neoplasms (MPNs), including myelofibrosis. Its lead candidate, AJ1‑11095, is a first‑in‑class Type II JAK2 inhibitor designed via a collaboration with Schrödinger using structure‑based drug design and large‑scale computational methods. Preclinical data show AJ1‑11095 maintains efficacy against MPN cells that become resistant to chronic Type I JAK2 inhibition and is intended to provide greater efficacy with potential disease‑modifying effects. The company plans to advance AJ1‑11095 into the clinic for myelofibrosis later this year and to use proceeds to push its broader MPN pipeline forward. Ajax emphasizes selective, structure‑guided approaches informed by its founding scientists’ cancer and structural biology insights. Ajax Therapeutics pursues uniquely selective small-molecule therapies targeting key cytokine signaling pathways that drive hematologic malignancies. The company combines disease and structural biology insights from its scientific founders with computational drug-discovery capabilities through a partnership with Schrödinger. Ajax’s pipeline centers on structurally enabled targets and is advanced via integrated discovery work with Schrödinger scientists to design compounds with desired selectivity and drug-like properties. The company began as an academic consortium and was founded in 2019, leveraging clinical and research collaborations with institutions such as Memorial Sloan Kettering Cancer Center and NYU Langone Health. Proceeds from the recent financing will support advancement of lead programs toward the clinic, sustain the discovery pipeline, and potentially expand research beyond hematologic malignancies. Ajax also plans to build out its scientific and technical leadership team as it advances its programs.